|Day Low/High||3.28 / 3.48|
|52 Wk Low/High||3.16 / 6.98|
In trading on Wednesday, shares of Galectin Therapeutics Inc crossed below their 200 day moving average of $5.17, changing hands as low as $5.14 per share. Galectin Therapeutics Inc shares are currently trading off about 4.4% on the day.
In trading on Friday, shares of Galectin Therapeutics Inc crossed above their 200 day moving average of $5.00, changing hands as high as $5.13 per share. Galectin Therapeutics Inc shares are currently trading up about 6.7% on the day.
Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALT options chain for the new September 21st contracts and identified one put and one call contract of particular interest.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
In recent trading, shares of Galectin Therapeutics Inc have crossed above the average analyst 12-month target price of $8.33, changing hands for $8.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects
The broad protection of these patents opens doors to partnerships in the world's second- and third-largest pharmaceutical markets
In trading on Tuesday, shares of Galectin Therapeutics Inc touched a new 52-week high of $6.74/share. That's a 617.02% rise, or $5.8 per share from the 52-week low of $0.94 set back on 01/23/2017.
Levi & Korsinsky announces it has commenced an investigation of Galectin Therapeutics, Inc.
Company to Host Investor Conference Call at 8:30 A.M. ET
The objective response rate in advanced melanoma was 62.5% (five of eight subjects)
Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.